Eric Hughes

6.8k total citations · 1 hit paper
62 papers, 2.9k citations indexed

About

Eric Hughes is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Eric Hughes has authored 62 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Hepatology, 32 papers in Epidemiology and 18 papers in Infectious Diseases. Recurrent topics in Eric Hughes's work include Hepatitis C virus research (44 papers), Hepatitis B Virus Studies (23 papers) and Liver Disease Diagnosis and Treatment (18 papers). Eric Hughes is often cited by papers focused on Hepatitis C virus research (44 papers), Hepatitis B Virus Studies (23 papers) and Liver Disease Diagnosis and Treatment (18 papers). Eric Hughes collaborates with scholars based in United States, Germany and Japan. Eric Hughes's co-authors include Peter Cresswell, Peter Cresswell, Fiona McPhee, Craig Hammond, Robert J. Fontana, Hiroki Ishikawa, Kazuaki Chayama, Hiromitsu Kumada, Joji Toyota and Stephanie Noviello and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and The Journal of Experimental Medicine.

In The Last Decade

Eric Hughes

61 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence

2016 331 citations Robert J. Fontana, Fiona McPhee et al. Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eric Hughes United States	26	1.8k	1.7k	654	575	563	62	2.9k
Nobuhiko Hiraga Japan	31	2.2k 1.2×	2.1k 1.3×	360 0.6×	389 0.7×	465 0.8×	89	3.0k
Mina Nakagawa Japan	25	1.5k 0.8×	1.2k 0.7×	481 0.7×	272 0.5×	524 0.9×	74	2.3k
Kazumoto Murata Japan	30	1.5k 0.8×	1.3k 0.8×	448 0.7×	346 0.6×	653 1.2×	135	2.7k
Ranjit Ray United States	33	2.2k 1.2×	1.9k 1.1×	677 1.0×	517 0.9×	868 1.5×	70	3.6k
Guofeng Cheng United States	20	2.5k 1.4×	2.1k 1.3×	310 0.5×	418 0.7×	528 0.9×	35	3.0k
Keril J. Blight United States	12	2.9k 1.6×	2.2k 1.3×	327 0.5×	430 0.7×	670 1.2×	14	3.4k
C Pasquinelli United States	24	2.7k 1.5×	2.8k 1.7×	398 0.6×	497 0.9×	395 0.7×	37	3.5k
Yasuhiro Asahina Japan	31	3.8k 2.1×	3.1k 1.8×	409 0.6×	419 0.7×	516 0.9×	129	4.5k
Christoph Neumann‐Haefelin Germany	35	2.3k 1.3×	1.8k 1.1×	1.7k 2.6×	396 0.7×	593 1.1×	111	4.0k
Eiji Mita Japan	32	2.4k 1.3×	2.0k 1.2×	275 0.4×	196 0.3×	540 1.0×	120	3.3k

Countries citing papers authored by Eric Hughes

Since Specialization

Citations

This map shows the geographic impact of Eric Hughes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Hughes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Hughes more than expected).

Fields of papers citing papers by Eric Hughes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Hughes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Hughes. The network helps show where Eric Hughes may publish in the future.

Co-authorship network of co-authors of Eric Hughes

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Hughes. A scholar is included among the top collaborators of Eric Hughes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Hughes. Eric Hughes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Draghia‐Akli, Ruxandra, Sarah W. Read, & Eric Hughes. (2024). Overview of ACTIV trial-specific lessons learned. Journal of Clinical and Translational Science. 8(1). e149–e149. 1 indexed citations

Adam, Stacey J., Timothy G. Buchman, Judith S. Currier, et al.. (2024). Preparing better: Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) therapeutics trials lessons learned: A call to the future. Journal of Clinical and Translational Science. 8(1). e150–e150.

Wood, Claire, Kieren G. Hollingsworth, Eric Hughes, et al.. (2023). Is ongoing testosterone required after pubertal induction in Duchenne muscular dystrophy?. Endocrine Connections. 12(12). 6 indexed citations

Zhu, Li, Hanbin Li, Phyllis Chan, et al.. (2018). Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection. Infectious Diseases and Therapy. 7(2). 261–275. 4 indexed citations

Chan, Phyllis, Hanbin Li, Li Zhu, et al.. (2017). Population Pharmacokinetic Analysis of Daclatasvir in Subjects with Chronic Hepatitis C Virus Infection. Clinical Pharmacokinetics. 56(10). 1173–1183. 11 indexed citations

Bartolini, Barbara, Raffaella Lionetti, Emanuela Giombini, et al.. (2015). Dynamics of HCV genotype 4 resistance-associated variants during virologic escape with pIFN/RBV+daclatasvir: A case study using ultra deep pyrosequencing. Journal of Clinical Virology. 66. 38–43. 11 indexed citations

Bronowicki, Jean–Pierre, Vlad Ratziu, Adrián Gadano, et al.. (2014). Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C. Journal of Hepatology. 61(6). 1220–1227. 21 indexed citations

Bronowicki, J.‐P., Vlad Ratziu, Adrián Gadano, et al.. (2013). 1420 ASUNAPREVIR WITH PEGINTERFERON-ALFA AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE-1 OR -4 CHRONIC HEPATITIS C: SVR24 RESULTS FROM A RANDOMIZED PHASE 2B STUDY (AI447016). Journal of Hepatology. 58. S571–S572. 10 indexed citations

Silva, Marcelo, Michelle Treitel, Donald J. Graham, et al.. (2013). Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3. Journal of Hepatology. 59(1). 31–37. 35 indexed citations

10.

Hulskotte, Ellen G. J., Hwa-ping Feng, Fengjuan Xuan, et al.. (2012). Pharmacokinetic Interactions Between the Hepatitis C Virus Protease Inhibitor Boceprevir and Ritonavir-Boosted HIV-1 Protease Inhibitors Atazanavir, Darunavir, and Lopinavir. Clinical Infectious Diseases. 56(5). 718–726. 58 indexed citations

11.

Treitel, Michelle, Thomas Marbury, Richard A. Preston, et al.. (2012). Single-Dose Pharmacokinetics of Boceprevir in Subjects with Impaired Hepatic or Renal Function. Clinical Pharmacokinetics. 51(9). 619–628. 34 indexed citations

12.

Suzuki, Yoshiyuki, Kenji Ikeda, Fumitaka Suzuki, et al.. (2012). Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. Journal of Hepatology. 58(4). 655–662. 179 indexed citations

13.

Fontana, Robert J., Eric Hughes, Henry D. Appelman, et al.. (2012). Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transplantation. 18(9). 1053–1059. 51 indexed citations

14.

Vermehren, Johannes, S. Süsser, Christian M. Lange, et al.. (2011). Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa‐2b. Journal of Viral Hepatitis. 19(2). 120–127. 39 indexed citations

15.

Süsser, S., Christoph Welsch, Yalan Wang, et al.. (2009). Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus–infected patients†. Hepatology. 50(6). 1709–1718. 252 indexed citations

16.

Cresswell, Peter, Balasubramanian Arunachalam, Naveen Bangia, et al.. (1999). Thiol oxidation and reduction in MHC-restricted antigen processing and presentation. Immunologic Research. 19(2-3). 191–200. 20 indexed citations

17.

Hughes, Eric & Peter Cresswell. (1998). The thiol oxidoreductase ERp57 is a component of the MHC class I peptide-loading complex. Current Biology. 8(12). 709–713. 162 indexed citations

18.

Cresswell, Peter & Eric Hughes. (1997). Protein degradation: The ins and outs of the matter. Current Biology. 7(9). R552–R555. 30 indexed citations

19.

Hughes, Eric, et al.. (1996). The protease inhibitor, N-acetyl-L-leucyl-L-leucyl-leucyl-L-norleucinal, decreases the pool of major histocompatibility complex class I-binding peptides and inhibits peptide trimming in the endoplasmic reticulum.. The Journal of Experimental Medicine. 183(4). 1569–1578. 59 indexed citations

20.

Arnold, Danièle, James J. Driscoll, Matthew J. Androlewicz, et al.. (1992). Proteasome subunits encoded in the MHC are not generally required for the processing of peptides bound by MHC class I molecules. Nature. 360(6400). 171–174. 188 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact